Press Releases

NEWSROOM

Press Releases by Agendia

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025

News

Press Releases

Agendia Appoints Two Industry Veterans to Board of Directors

kevin2019-05-31T19:59:31-04:00

PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 31 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and François Ferré, Ph.D. to Read More

Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal

kevin2019-05-21T21:47:37-04:00

PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 21 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today an agreement with Imegen (Valencia, Spain), for the exclusive distribution of the Read More

New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy

kevin2025-04-28T13:54:47-04:00

PRESS RELEASE ER+ breast cancer patients reclassified as ER+ basal-type demonstrated significant response to chemotherapy underscoring critical role of advanced diagnostic tools Results published in Nature Publishing Group’s npj Breast Cancer IRVINE, CALIF., U.S., Read More

Agendia Announces Creation of New Center of Innovation and R&D Excellence

kevin2019-04-17T20:01:06-04:00

PRESS RELEASE Simultaneous creation of Global Lab Center of Excellence IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 17 April 2019 – Agendia, Inc., a world leader in precision oncology, announced today that it has created Read More

Positive Assessment Issued for Agendia’s MammaPrint®

kevin2019-01-09T19:48:34-05:00

PRESS RELEASE Determination finds that Agendia’s MammaPrint® Breast Cancer Risk of Recurrence test improves net health outcome for patients and positions the test well for further adoption by health insurance plans in the U.S. IRVINE, Read More

New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment

kevin2018-12-07T13:30:13-05:00

PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment BluePrint reclassified 85 percent of tumors identified as HER2-amplified by IHC/FISH to non-HER2 Read More

New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions

kevin2018-12-05T23:33:13-05:00

PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium IRVINE, CA, AMSTERDAM, Read More

Previous 131415 Next

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

View Our Video

Latest Data

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

View the data

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View the portrait series

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.
c	6 months 2 days	Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a	never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
uuid	1 year 1 month	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.
VISITOR_INFO1_LIVE	6 months	YouTube sets this cookie to measure bandwidth, determining whether the user gets the new or old player interface.
VISITOR_PRIVACY_METADATA	6 months	YouTube sets this cookie to store the user's cookie consent state for the current domain.
YSC	session	Youtube sets this cookie to track the views of embedded videos on Youtube pages.
yt-remote-cast-installed	session	The yt-remote-cast-installed cookie is used to store the user's video player preferences using embedded YouTube video.
yt-remote-connected-devices	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-device-id	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-fast-check-period	session	The yt-remote-fast-check-period cookie is used by YouTube to store the user's video player preferences for embedded YouTube videos.
yt-remote-session-app	session	The yt-remote-session-app cookie is used by YouTube to store user preferences and information about the interface of the embedded YouTube video player.
yt-remote-session-name	session	The yt-remote-session-name cookie is used by YouTube to store the user's video player preferences using embedded YouTube video.
yt.innertube::nextId	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
ytidb::LAST_RESULT_ENTRY_KEY	never	The cookie ytidb::LAST_RESULT_ENTRY_KEY is used by YouTube to store the last search result entry that was clicked by the user. This information is used to improve the user experience by providing more relevant search results in the future.

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a	never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.

Cookie	Duration	Description
c	6 months 2 days	Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.
uuid	1 year 1 month	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	6 months	YouTube sets this cookie to measure bandwidth, determining whether the user gets the new or old player interface.
VISITOR_PRIVACY_METADATA	6 months	YouTube sets this cookie to store the user's cookie consent state for the current domain.
YSC	session	Youtube sets this cookie to track the views of embedded videos on Youtube pages.
yt.innertube::nextId	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Cookie	Duration	Description
yt-remote-cast-installed	session	The yt-remote-cast-installed cookie is used to store the user's video player preferences using embedded YouTube video.
yt-remote-connected-devices	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-device-id	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-fast-check-period	session	The yt-remote-fast-check-period cookie is used by YouTube to store the user's video player preferences for embedded YouTube videos.
yt-remote-session-app	session	The yt-remote-session-app cookie is used by YouTube to store user preferences and information about the interface of the embedded YouTube video player.
yt-remote-session-name	session	The yt-remote-session-name cookie is used by YouTube to store the user's video player preferences using embedded YouTube video.
ytidb::LAST_RESULT_ENTRY_KEY	never	The cookie ytidb::LAST_RESULT_ENTRY_KEY is used by YouTube to store the last search result entry that was clicked by the user. This information is used to improve the user experience by providing more relevant search results in the future.

NEWSROOM

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting

Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting

Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025

News

Press Releases

Agendia Appoints Two Industry Veterans to Board of Directors

Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal

New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy

Agendia Announces Creation of New Center of Innovation and R&D Excellence

Positive Assessment Issued for Agendia’s MammaPrint®

New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment

New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions

RON KALFUS

STEPHANIE BYWATER